Article Sidebar

PDF
Issue: Vol. 562 No. 1 (2026)
Section: Các bài báo
DOI: 10.51298/vmj.v562i1.18432
Date Published: 10/08/2026
Views 22
Downloads 13
How to Cite
Tạ, T. H. T., Lê, T. L., Lê, T. H., & Nguyễn, T. N. T. (2026). ASSESSING CARDIOVASCULAR RISK IN PATIENTS WITH PSORIASIS ARTHRITIS USING THE SCORE2 AND SCORE2OP SCALES. Vietnam Medical Journal, 562(1). https://doi.org/10.51298/vmj.v562i1.18432

ASSESSING CARDIOVASCULAR RISK IN PATIENTS WITH PSORIASIS ARTHRITIS USING THE SCORE2 AND SCORE2OP SCALES

Thị Hương Trang Tạ1,2, , Thị Liễu Lê2, Thị Hường Lê1, Thị Ngọc Trâm Nguyễn1
1 Trường Đại Học Y Hà Nội
2 Bệnh viện Bạch Mai

Main Article Content

Abstract

Objective: Psoriatic Arthritis (PsA) is a chronic inflammatory joint disease, simultaneously affecting the skin, joints, and multiple extra-articular organs. PsA patients have an increased cardiovascular (CV) risk due to the combination of chronic inflammation and traditional cardiovascular risk factors. Assessing the CV risk in PsA patients helps to modify risk factors and improve the disease prognosis.


Background: this study aims to predict cardiovascular risk using the SCORE 2 and SCORE 2 OP scales and some related factors in patients with psoriatic arthritis.


Subject and methods: The study was conducted on 55 PsA patients at the Centre for Rheumatology of Bach Mai Hospital from August 2024 to July 2025.


Results: The mean cardiovascular risk was 6.78 ± 6.2 (%), with 32.7% of patients presenting low-to-moderate risk, 47.3% high risk, and 20% very high risk. The 10-year CV risk in PsA patients was associated with disease duration, aged, sex, disease activity.


Conclusion: Cardiovascular risk assessment should be routinely performed in patients with psoriatic arthritis.

Keywords

cardiovascular risk, Psoriatic Arthritis

Article Details

References

1. Dey M, Nikiphorou E. Cardiovascular comorbidities in psoriatic arthritis: state of the art. Ther Adv Musculoskelet Dis. 2024;16:1759720X241274537.
2. Ernste FC, Sánchez-Menéndez M, Wilton KM, Crowson CS, Matteson EL, Maradit Kremers H. Cardiovascular risk profile at the onset of psoriatic arthritis: a population-based cohort study. Arthritis Care Res (Hoboken). 2015;67(7):1015-1021.
3. Eder L, Wu Y, Chandran V, Cook R, Gladman DD. Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. Ann Rheum Dis. 2016;75(9):1680-1686.
4. Nguyen HT, Vu AT, Pham NTU, et al. Comorbidity Burden and Treatment Patterns of Psoriasis in Vietnam: Real-World Data from the EXPAND Study. Dermatol Ther (Heidelb). 2023;13(12):3193-3208.
5. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76(1):17-28.
6. Szentpetery A, Haroon M, FitzGerald O. Cardiovascular Comorbidities in Psoriatic Disease. Rheumatol Ther. 2019;7(1):5-17.
7. Triantafyllias K, Liverakos S, Muthuraman M, Cavagna L, Parodis I, Schwarting A. Cardiovascular Risk Evaluation in Psoriatic Arthritis by Aortic Stiffness and the Systemic Coronary Risk Evaluation (SCORE): Results of the Prospective PSOCARD Cohort Study. Rheumatol Ther. 2024;11(4):897-911.
8. Degboé Y, Koch R, Zabraniecki L, et al. Increased Cardiovascular Risk in Psoriatic Arthritis: Results From a Case-Control Monocentric Study. Front Med (Lausanne). 2022;9:785719.
9. Egeberg A, Skov L, Hansen PR, et al. Duration of psoriatic arthritis as a risk factor for myocardial infarction. Rheumatol Adv Pract. 2018;2(1):rky011.
10. Jamnitski A, Symmons D, Peters MJL, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2013;72(2):211-216.
11. Lam SHM, Cheng IT, Li EK, et al. DAPSA, carotid plaque and cardiovascular events in psoriatic arthritis: a longitudinal study. Ann Rheum Dis. 2020;79(10):1320-1326.